Brain+ AS (OCSE:BRAINP) Change In Receivables : kr1.18 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Brain+ AS Change In Receivables?

Brain+ AS's change in receivables for the quarter that ended in Dec. 2023 was kr0.71 Mil. It means Brain+ AS's Accounts Receivable declined by kr0.71 Mil from Jun. 2023 to Dec. 2023 .

Brain+ AS's change in receivables for the fiscal year that ended in Dec. 2023 was kr1.18 Mil. It means Brain+ AS's Accounts Receivable declined by kr1.18 Mil from Dec. 2022 to Dec. 2023 .

Brain+ AS's Accounts Receivable for the quarter that ended in Dec. 2023 was kr0.03 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Brain+ AS's liquidation value for the six months ended in Dec. 2023 was kr-20.47 Mil.

Brain+ AS Change In Receivables Historical Data

The historical data trend for Brain+ AS's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Brain+ AS Change In Receivables Chart

Brain+ AS Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

0.05

-1.02

2.21

1.18

Brain+ AS Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Receivables	Get a 7-Day Free Trial			-0.83	1.10	1.11	0.47	0.71

Brain+ AS Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr1.18 Mil.

Brain+ AS (OCSE:BRAINP) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Brain+ AS's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.031	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Brain+ AS's accounts receivable are only considered to be worth 75% of book value:

Brain+ AS's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	3.091	-	23.585	+	0.75 * 0.031	+	0.5 * 0
=	-20.47

Brain+ AS Change In Receivables Related Terms

Thank you for viewing the detailed overview of Brain+ AS's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Brain+ AS (OCSE:BRAINP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Brain+ AS (OCSE:BRAINP) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

Kobmagergade 53, 3rd Floor, Copenhagen, DNK, DK-1150

Website

https://www.brain-plus.com

Brain+ AS is a digital therapeutics company. It restores patients' quality of life by treating and detecting a cognitive decline in Alzheimer's disease and dementia through digital means. It has developed a set of Digital Medicine technologies. Its product pipeline includes CST Therapist Companion, and CST Home Companion; CST Home Care; CST for Mild Cognitive Impairment (MCI).

Brain+ AS (OCSE:BRAINP) Headlines

No Headlines